A B S T R A C T Trypsin-activated pig plasmin and human plasmin activated by streptokinase (SK)caused aggregation of a suspension of washed platelets from human, rabbit, or pig blood. The platelet aggregation was reversible, but it was accompanied by a significant release of adenine nucleotides, serotonin, and platelet fibrinogen. Platelet fibrinogen was eventually digested. The effect of plasmin on platelets was inhibited by soybean trypsin inhibitor, epsilon aminocaproic acid, Persantin, prostaglandin El, and phenylbutazone. Short treatment of platelets with plasmin enhanced their sensitivity to ADP; however, this sensitivity was lost during longer incubation with plasmin. This enzyme also made platelets less sensitive to collagen and thrombin.
INTRODUCTION
It is well established that platelet aggregation and the platelet release reaction can be brought about by several proteolytic enzymes such as thrombin (1) papain, trypsin, and pronase (2). Niewiarowski, Gurewich, Senyi, and Mustard have recently reported that plasmin causes aggregation of suspensions of washed human, pig, and rabbit platelets. This aggregation was accompanied by the release of serotonin (3) . The purpose of this work is to investigate further the effects of plasmin on platelet function in vitro as well as the effects of the infusion of streptokinase (SK)' which leads to the activation of fibrinolytic system in vivo. It was found that plasmin causes reversible aggregation of platelets accompanied by a significant release of adenine nucleotides, serotonin, and platelet fibrinogen which is subsequently digested. The release of platelet constituents and reversible platelet aggregation also occurred in vivo after injection of SK. We present evidence that these phenomena may contribute to the hemostatic defect in primary fibrinolysis. These assays were performed as described previously (7) .
METHODS
[3H] 5-HT (Amersham/Searle Corp., Arlington Heights, Ill.) had specific activity of 5.4 mCi/mg.
Adenine nucleotide release from platelet suspension was measured as described previously (7) .
Lactic dehydrogenase (LDH) 5 GCi of this compound was added to 12.5 ml of platelet suspension in the first washing fluid, which was subsequently divided into five equal portions. Then each of five receiver rabbits was injected with 2.5 ml of the labeled platelet suspension. After 16 h, and immediately before SK injection, 10 ml of blood was obtained from each rabbit and mixed with ACD.
Another sample of blood was obtained 10 min after SK injection. Platelets were prepared from these samples of blood and adjusted to the final count of 10'/ml. After sonication, radioactivity was counted in 0.1-ml samples.
The bleeding time in rabbits. The effect of SK on the bleeding time was studied in a mesentery preparation (12, 13) . Rabbits (14) .
RESULTS
The effect of plasmin on platelets in vitro. The addition of plasmin to the washed platelets of rabbit produced their aggregation response, which reached its maximum after approximately S min. After this period of time, platelet clumps started to deaggregate (Fig. 2) Incubation time in minutes FIGURE 4 Light transmission changes in the suspension of rabbit platelets aggregated by plasmin, collagen, and thrombin. Following reagents were added to 1 ml samples of platelets: 0.1 ml of 0.5% plasmin; 0.1 ml collagen; 0.1 ml plasmin and 0.1 ml of collagen; 0.1 ml of thrombin (0.5 U/ml); 0.1 ml of thrombin (0.5 U/ml) and 0.1 ml of 0.5% plasmin.
sitivity of plasmin-treated platelets to thrombin and collagen. Fig. 4 shows the results of an experiment in which each of three stimuli, plasmin, collagen, and thrombin added to platelet suspension alone produced more aggregation than the mixture of collagen and plasmin or the mixture of thrombin and plasmin. In the next experiment, pig plasmin was incubated with rabbit, pig, or human platelets for 3 min. The extent of platelet aggregation and the release of radioactivity from ['H]5-HT-labeled platelets were similar in all three species (Table IV) The effects of SK infusion to rabbits on platelets in vivo. The infusion of SK to rabbits in a dose of 10,000 U/kg body weight produced a pronounced activation of fibrinolysis in whole blood and in euglobulin fraction of plasma, and slight but significant prolongation of the thrombin clotting time of platelet-poor plasma (Table  V) . This dose of SK caused a significant drop of platelet count in whole blood between the 2nd and 5th min after injection (Table VI * 1-ml samples of platelet suspension (10') were incubated for 3 min with (a) 0.1 ml 0.25% plasminogen and 0.1 ml 0.9% NaCl: (b) 0.1 ml SK (500 U/ml) and 0.1 ml 0.9% NaCl: (c) 0.1 ml 0.25% plasminogen and 0.1 ml SK (500 U/ml); (d) 0.1 ml 0.5% pig plasmin. The mixture of SK and plasminogen was preincubated for 3 min before addition to the platelet suspension.
In one experiment, incubation of rabbit platelet suspension for 7 min with 0. 3.14 mg/ml to 1.80 mg/ml in a group of rabbits receiving Tyrode and from 3.11 mg/ml to 2.08 mg/ml in the Persantin-treated rabbits. The level of plasma fibrinogen determined as clottable protein was not changed. It can be seen that Persantin protected rabbits from losing an important portion of platelet fibrinogen but it did not affect the level of plasma fibrinogen.
In the following experiments, rabbit blood was collected and mixed with 3.8% sodium citrate in a proportion of 9 vol of blood to 1 vol of citrate. Subsequently, platelet-rich plasma was prepared from this blood to study platelet aggregation by collagen. Fig. 5 shows that the injection of SK caused a significant drop of platelet sensitivity to collagen, 10 min after injection. Infusion of Persantin (7 mg/kg weight) resulted in only a slight inhibition of collagen-induced aggregation. However, platelets obtained from rabbits receiving injection of both Persantin and SK were much more sensitive to collagen than the platelets from rabbits injected with SK alone.
The bleeding time from the proximal mesenteric venule of rabbits 10 min after SK injection was 5 times longer than that of the control rabbits injected with Tyrode solution (Table XI) . Injection of Persantin in a dose of 7 mg/kg body weight and injection of EACA in a dose of 500 mg/kg body weight had no effect on the bleeding time. However, if Persantin was injected 10 min before SK injection, no significant prolongation of the bleeding time over controls was observed. Pretreatment of rabbits with EACA also exerted a protective effect which was, however, less pronounced.
DISCUSSION
It can be concluded that plasmin causes reversible platelet aggregation and release reaction as demonstrated by the release of [8H]5-HT radioactivity and of adenine nucleotides from washed platelets. The LDH, a cytoplasmic marker, is retained in platelets, thus indicating that no lysis of platelets occurred. Plasmin action on platelets is inhibited as well by the inhibitors of plasmin (SBTI, EACA) as by the inhibitors of platelet release reaction (phenylbutazone, Persantin, PGE1). In contrast, thrombin effects on platelets are not inhibited by SBTI and EACA but they are completely inhibited by hirudin (3). A short preincubation of platelets with plasmin enhances ADP-induced aggregation and in this respect plasmin acts similarly to thrombin (15, 16) .
The loss of platelet sensitivity to ADP during longer incubation with plasmin may depend on the accumulation of adenine nucleotides in the suspending fluid and on the digestion of platelet fibrinogen.
Platelet fibrinogen undergoes almost complete degradation during plasmin action on platelets. The measurement of fibrinogen level in platelets by the staphylococcal clumping method gave similar values to those obtained by Keenan and Solum (17) , who used immunoassay.
Neither PGE1 nor Persantin inhibits the plasmin action on purified fibrinogen or on the fibrinogen in platelet suspension homogenized by sonification. On the other hand, these drugs added to intact platelets protect at least 50% of platelet fibrinogen from the plasmin degradation. It can be suggested that PGE1 and Persantin may protect platelet fibrinogen by inhibiting its release from platelets. It is likely that platelet fibrinogen is first released and then digested by plasmin. In the presence of PGE1 or Persantin, plasmin may degrade only the fibrinogen adsorbed on the platelet membranes while fibrin- (13) . These authors suggested that the digestion of fibrin by activated fibrinolytic enzymes in the hemostatic plug may be responsible for bleeding. However, Kjaerheim and Hovig (27) failed to demonstrate fibrin in the interior of hemostatic plug formed in the mesenteric vessels and they suggested that fibrin possibly exerts its action at a later stage of hemostasis, in sealing and enclosing the relatively vulnerable plug.
It is possible that the digestion of fibrin in the hemostatic plug is responsible for prolongation of the secondary bleeding. However, prolongation of the primary bleeding likely reflects platelet defects caused by plasmin. The nature of the plasmin-induced platelet defect, consisting of the decreased platelet sensitivity to collagen and the prolonged primary bleeding time, is not clear. The decrease of plasma and platelet fibrinogen could not account for these abnormalities since the concentration of fibrinogen necessary to support platelet aggregation appears to be much lower (28, 29) . There is an intriguing possibility that after injection of SK, platelets have been rendered defective by a depletion of their storage pool. This possibility is supported by experiments in which Persantin was found to be a potent inhibitor of plasmininduced platelet aggregation. Injection of Persantin pro- tected rabbit platelets against the effect of SK. These rabbit platelets retained their serotonin and responded better to collagen. In addition, the SK-induced prolongation of bleeding time did not occur in rabbits receiving Persantin. Cucuianu, Nishizawa, and Mustard (30) found that higher doses of Persantin completely inhibited collagen-induced platelet aggregation and increased bleeding time. However, the dose used in our experiments (7 mg/kg) did not increase bleeding and produced only small inhibition of collagen-induced aggregation.
It is generally accepted that the bleeding in patients receiving SK may depend on several causes, such as digestion of fibrinogen, digestion of fibrin in the hemostatic plug (13) , and the formation of fibrinogen degradation products that may inhibit clotting (21, (31) (32) (33) and platelet aggregation (25, (33) (34) (35) (36) (37) . However, recent observations indicate that the "antiaggregating activity" of degradation products is low and not specific (3, 38) .
Our experiments suggest that the platelet defect resulting from the plasmin action may be an important cause of bleeding in patients receiving thrombolytic therapy as well as in patients with systemic activation of fibrinolysis due to other factors. It can also be suggested that agents inhibiting platelet release reaction, such as Persantin, could be used in certain circumstances for the control of bleeding. The dosage of persantin administered to rabbits was at least 10 times higher than the standard dosage of this drug used in human therapy (39) . It is difficult to extrapolate from the study on animals to clinical conclusions. It seems, however, that our results warrant further investigations on the simultaneous use of SK and other antiplatelet agents in animals and in man.
